EICHOR
● Completed
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (15)
| UCI Health Irvine Hospital | Irvine, California, United States | — |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | — |
| University of California Irvine Medical Center Chao Family Comprehensive Cancer Center | Orange, California, United States | — |
| Oncology Hematology Associates | Springfield, Missouri, United States | — |
| Hunterdon Hematology Oncology | Flemington, New Jersey, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
| Changhua Christian Hospital | Changhua, Taiwan | — |
| Kaohsiung Medical University Hospital | Kaohsiung City, Taiwan | — |
| Chi Mei Medical Center Liu Ying | Liou Ying Township, Taiwan | — |
| Taichung Veterans General Hospital | Taichung, Taiwan | — |
| National Taiwan University Hospital | Taipei, Taiwan | — |
| Taipei Medical University | Taipei, Taiwan | — |
+ 3 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.